Brain serotonin transporter binding in former users of MDMA ('ecstasy')

British Journal of Psychiatry

Volumn 194, Issue 4, 2009, Pages 355-359

  Selvaraj, Sudhakar ^a,b   Hoshi, Rosa ^c   Bhagwagar, Zubin ^d   Murthy, Naga Venkatesha ^a   Hinz, Rainer ^e   Cowen, Philip ^b   Curran, H Valerie ^c   Grasby, Paul ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b WARNEFORD HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; SEROTONIN BRAIN LEVEL;

ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME;

EID: 64149084201     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.050344     Document Type: Article

References (32)

1. United Nations International Narcotics Control Board. Annual Report 2006. United Nations, 2007.
2. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96: 678-85.
3. Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y. Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 1998; 805: 241-54.
4. Battaglia G, Yen SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987; 242: 911-6.
5. Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000; 42: 5-10.
6. Szabo Z, McCann UD, Wilson aa, scheffel U, Owonikoko T, Mathews WB, et al. Comparison of (+)-(11)C-MCN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002; 43: 678-92.
7. Easton N, Marsden CA. Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 2006; 20: 194-210.
8. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado Ml. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003; 55: 463-508.
9. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999; 19: 5096-107.
10. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-lV Axis I Disorders - Clinician Version (SCID-CV). American psychiatric Press, 1997.
11. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
12. Spielberger CE, Garsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, 1970.
13. Eysenck HJ, Eysenck SBG. Manual of the Eysenck Personality Scales (EPS Adult). Hodder and Stoughton, 1991.
14. Baddeley A, Emslie H, Nimmo smith I. The Spot-the-word Test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol 1993; 32: 55-65.
15. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 2000; 43: 3103-10.
16. 11C]DASB. Am J Psychiatry 2007; 164: 1858-65.
17. 11CIDASB in healthy controls. J Cereb Blood Flow Metab 2008; 28: 1478-90.
18. 11CIDASB. Neuropsychopharmacology 2005; 30: 1741-50.
19. Hammers A, Koepp MJ, Free SL, Brett M, Richardson MP, Labbé C, et al. Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp 2002; 15: 165-74.
20. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005; 32: 123-8.
21. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-7.
22. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
23. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993; 13: 15-23.
24. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 2006; 20: 164-75.
25. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, et al. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 2004; 161: 1181-9.
26. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedloxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch Gen Psychiatry 2001; 58: 901-6.
27. Thomasius R, zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006; 20: 211-25.
28. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, wartberg L, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003; 167: 85-96.
29. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci 1995; 15: 5476-85.
30. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, et al. Behavioral and neurochemical consequences of longterm intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 2004; 29: 1270-81.
31. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 2003; 18: 507-17.
32. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358: 1864-9.